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Gender Differences in Melanoma Survival: Female
Patients Have a Decreased Risk of Metastasis
Arjen Joosse1, Esther de Vries1,5, Renate Eckel2, Tamar Nijsten3, Alexander M.M. Eggermont4, Dieter Ho¨lzel2,
Jan Willem W. Coebergh1,5 and Jutta Engel2, for the Munich Melanoma Group6
Female melanoma patients generally exhibit significantly longer survival than male patients. This population-
based cohort study aimed to investigate gender differences in survival and disease progression across all stages
of cutaneous melanoma. A total of 11,774 melanoma cases extracted from the Munich Cancer Registry
(Germany), diagnosed between 1978 and September 2007, were eligible to enter the study. Hazard ratios (HRs)
and 95% confidence intervals (CIs), adjusted for tumor and patient characteristics, were estimated for the end
points of survival, regional and systemic progression, and survival after progression. A significant female
advantage was observed for melanoma-specific survival (adjusted HR 0.62; 95% CI 0.56–0.70). Women were at a
lower risk of progression (HR 0.68; 95% CI 0.62–0.75), including a lower risk of lymph node metastasis (HR 0.58;
95% CI 0.51–0.65) and visceral metastases (HR 0.56; 95% CI 0.49–0.65). They retained a significant survival
advantage after first progression (HR 0.81; 95% CI 0.71–0.92) and lymph node metastasis (HR 0.80; 95% CI
0.66–0.96), but this became borderline significant (HR 0.88; 95% CI 0.76–1.03) after visceral metastasis. Localized
melanomas in women had a lower propensity to metastasize, resulting in a better survival when compared
with men, even after first disease progression. These results suggest differences in tumor–host interaction
across gender.
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INTRODUCTION
In 1967, Wallace H Clark (Clark et al., 1969) noted that
melanoma was more aggressive in males. Since then,
numerous studies have consistently confirmed gender to be
an independent prognostic factor after adjustment for, e.g.,
age, Breslow thickness, histological subtype, body site
(Downing et al., 2006; Lasithiotakis et al., 2008; de Vries
et al., 2008), ulceration (Balch et al., 2001b; Azzola et al.,
2003), vascular invasion (Nagore et al., 2005), mitotic rate,
Clark level (Azzola et al., 2003), and sentinel lymph node
positivity (Scoggins et al., 2006; Lasithiotakis et al., 2008).
Hence, a biological basis was suggested to underlie this
female survival advantage (Lasithiotakis et al., 2008; de Vries
et al., 2008). Several investigators hypothesized female
melanoma patients to be somehow protected against
metastasis (Kemeny et al., 1998; Nieto et al., 2003;
Daryanani et al., 2005). However, the precise differences in
metastatic patterns across gender remain unclear. Some have
stated that gender influences only local cancer invasion
(Molife et al., 2001); others have hypothesized that the effect
is limited to lymphogenous (Richardson et al., 1999) or
hematogenous (Scoggins et al., 2006) metastasis. Given the
conflicting results (Kemeny et al., 1998; Balch et al., 2001b;
Hofmann et al., 2007), it also remains controversial whether
the superior female survival is restricted to early-stage
melanoma or also pertains to patients diagnosed with
metastatic disease.
This observational study assessed gender differences in
several phases of melanoma progression and across all
melanoma stages. We used data from the Munich Cancer
Registry (MCR).
RESULTS
Study population
Of the total of 11,734 patients analyzed, 49.3% were male
(Table 1). Between 1978 and 1992 most of the newly
registered melanoma patients were female, but after 1992
there was a higher incidence of male patients. Men exhibited
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a disadvantaged distribution for almost all prognostic
indicators (Table 1), being significantly older at diagnosis,
having thicker melanomas, and having more melanomas
Table 1. Descriptive data of study population: newly
diagnosed patients with cutaneous melanoma
recorded in the MCR
Males Females
N % N % P-value
Total 5,779 49.3% 5,995 50.7%
variable
Patient characteristics
Age
Median (y) 58.5 55.9
Mean (y) 57.2 55.9 o0.001
Year of MM diagnosis Overall o0.001
1978–1982 313 5.4% 438 7.4% o0.001
1983–1987 610 10.6% 673 11.3% 0.20
1988–1992 922 16.0% 1,063 17.9% 0.01
1993–1997 1,059 18.3% 970 16.3% o0.01
1998–2002 1,557 26.9% 1,475 24.8% 0.01
2003–2006 1,318 22.8% 1,336 22.4% 0.63
Primary tumor characteristics
Breslow thickness
Median (mm) 0.84 0.75
Mean (mm) 1.81 1.70 0.23
In categories: Overall o0.001
o1.0mm 2,942 50.9% 3,261 54.4% o0.001
1.01–2.0mm 1,003 17.4% 1,007 16.8% 0.52
2.01–4.0mm 695 12.0% 560 9.3% o0.001
44.0mm 415 7.2% 355 5.9% 0.01
Missing 724 12.5% 772 12.9% 0.48
Histology Overall o0.001
SSM 3,085 53.4% 3,091 51.9% 0.11
NM 1,313 22.7% 1,295 21.7% 0.21
LMM 377 6.5% 500 8.4% o0.001
ALM 121 2.1% 216 3.6% o0.001
Other/NOS 883 15.3% 853 14.3% 0.15
Site Overall o0.001
Head and neck 945 16.4% 881 14.8% 0.02
Trunk 2,503 43.3% 1,259 21.1% o0.001
Upper extremity 1,301 22.5% 1,311 22.0% 0.52
Lower extremity 933 16.1% 2,431 40.8% o0.001
NOS 97 1.7% 73 1.2% 0.04
Ulceration Overall 0.13
No 1,896 32.8% 1,913 32.1% 0.09
Table 1. Continued
Males Females
N % N % P-value
Yes 267 4.6% 237 4.0% 0.43
Missing 3,616 62.6% 3,805 63.9% 0.14
TNM stage at diagnosis
N stage at diagnosis Overall o0.001
N0/NX 5,481 94.8% 5,776 97.0%
N1+ 298 5.2% 179 3.0%
M stage at diagnosis Overall 0.01
M0 5,682 98.3% 5,891 98.9%
M1 97 1.7% 64 1.1%
Disease progression during follow-up
Disease progression? Overall o0.001
Yes 1,257 21.8% 934 15.7%
No 4,522 78.2% 5,021 84.3%
Local recurrence? Overall 0.50
Yes 266 4.6% 290 4.9%
No 5,513 95.4% 5,665 95.1%
In-transit/satellite
metastasis?1
Overall 0.10
Yes 52 0.9% 72 1.2%
No 5,727 99.1% 5,883 98.8%
Lymph node
metastasis?
Overall o0.001
Yes 805 13.9% 516 8.7%
No 4,979 86.1% 5,439 91.3%
Distant metastasis? Overall o0.001
Visceral metastasis 675 11.7% 406 6.8% o0.001
Distant skin/LN
metastasis
274 4.7% 247 4.1% 0.13
No distant
metastasis
4,830 83.6% 5,302 89.0% o0.001
Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna
melanoma; LN, lymph node; MCR, Munich Cancer Registry; MM,
malignant melanoma; NM, nodular melanoma; NOS, not otherwise
specified; SSM, superficial spreading melanoma; TNM stage, tumor–
node–metastasis stage.
1Of the total of 124 in-transit/satellite metastases, n=119 were in-transit
and n=5 were satellites.
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localized on the trunk or head and neck. In analyses of
histological subtypes, females had significantly more lentigo
maligna melanomas and acral lentiginous melanomas, but
the incidence of SSM and nodular melanoma did not differ
across gender. Males more often presented with lymph node
metastases or distant metastasis at diagnosis than did females
(5.2 vs. 3.0% and 1.7 vs. 1.1%, respectively). Whereas
overall disease progression, lymph node metastasis, and
distant metastasis occurred significantly more often in males
than in females, local recurrence and in-transit/satellite
metastases were equally common. Median follow-up time
of the total study population was 6.7 years (80 months).
Survival
Of the total 11,734 patients, 3,469 died during follow-up,
including 1,398 registered melanoma deaths. The crude
10-year overall survival rate was 70% and considerably
higher in females than in males (76 vs. 65%). Similarly,
adjusted overall survival for females was much better than for
males (adjusted hazard ratio (HR) 0.71; 95% confidence
interval (CI) 0.66–0.75; Table 2), which was even more
pronounced in melanoma-specific survival (adjusted HR
0.59; 95% CI 0.53–0.66). Breslow thickness was the only
confounder affecting the gender survival difference.
Subgroup analyses showed that neither ulceration nor the
proxy for menopausal status considerably affected survival
differences across gender (data not shown). Comparing our
survival plots according to stages I to IV with those of the
American Joint Committee on Cancer (AJCC) 2001 classifica-
tion validation resulted in an almost complete overlap. In the
subgroup with known ulceration status, the presence of
ulceration upstaged melanomas classified in Breslow thick-
ness categories. The best prognosis in stage IV patients was
observed for skin and distant lymph node metastases,
followed by lung metastases; the poorest prognosis was
for other visceral metastases. These observations are in
accordance with AJCC validation studies.
Progression after localized melanoma diagnosis
Females were at a lower risk of disease progression as
recorded at follow-up (adjusted HR 0.69; 95% CI 0.63–0.75;
Table 3). No significant differences across gender were
observed for local recurrence or in-transit/satellite metas-
tases. However, the probability of progressing to stage III
(lymph node metastasis) and stage IV (distant metastasis) was
significantly lower in women as compared with men
(adjusted HRs 0.58; 95% CI 0.51–0.65 and 0.64; 95% CI
0.57–0.71, respectively). Among distant metastasis subcate-
gories, gender did not significantly affect the occurrence of
skin metastases or distant lymph node metastasis. However,
the progression to visceral metastases was highly influenced
by gender (adjusted HR 0.53; 95% CI 0.46–0.61), with similar
estimates for the occurrence of liver, lung, and brain
metastases. Breslow thickness and primary tumor body site
were the only confounders consistently included in the
multivariable analyses. Subsequent full adjustment with all
available confounders did not greatly affect gender estimates
for disease progression (Table 3), nor did adjusting for
ulceration or menopausal status in the subgroup analyses
(data not shown).
Survival after melanoma progression
Out of 2,191 patients who progressed, 1,110 died from
melanoma (Table 4). After first progression of disease, women
retained a survival advantage of 16% as compared with
males (adjusted HR 0.84; 95% CI 0.74–0.95). This advantage
was also significant after in-transit/satellite and lymph node
metastasis, but borderline significant for survival after local
recurrence and distant metastasis. Overall, no significant
adjusted gender effects were observed for survival after any of
the subtypes of distant metastasis. However, the effect of
gender on survival after visceral metastasis also approached
significance (adjusted HR 0.87; 95% CI 0.74–1.01). Full
adjustment for all available confounders did not considerably
change the adjusted gender estimate. Owing to lack of
Table 2. Survival after melanoma diagnosis: multivariable analysis comparing females with males
Crude HR Adjusted HR2 Fully adjusted HR3
End point Events (%)1 HR 95% CI HR 95% CI Included confounder(s)2 HR 95% CI
Overall survival
Males 1,929 (33.3) 1.00 Ref 1.00 Ref Breslow 1.00 Ref
Females 1,540 (25.7) 0.67 0.63–0.72 0.71 0.66–0.75 0.69 0.64–0.74
Melanoma-specific survival
Males 851 (14.7) 1.00 Ref 1.00 Ref Breslow 1.00 Ref
Females 547 (9.1) 0.55 0.50–0.62 0.59 0.53–0.66 0.62 0.56–0.70
Abbreviations: CI, confidence interval; HR, hazard ratio.
1Absolute numbers of deaths that were observed and the percentages within the male/female groups.
2The following confounders were tested: age, year of diagnosis (YOD), primary tumor Breslow thickness (in AJCC (American Joint Cancer Classification
System) categories), histology and body site, and N-stage and M-stage at the time of diagnosis. If a confounder adjusted the male excessive risk of death by
X10%, it was considered an eligible confounder and was added to the adjusted Cox proportional hazards model.
3Adjusted for all confounders: age, year of diagnosis, primary tumor Breslow thickness, histology and localization, and N-stage and M-stage at the time of
diagnosis.
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power, subgroup analyses were not performed after disease
progression.
DISCUSSION
Although the female melanoma survival advantage has been
well established, there is little information on the gender
effect on progression patterns. To our knowledge, this is the
first study that not only analyzes gender survival differences
but also simultaneously takes into account all types of
melanoma progression. There have been speculations that
gender might influence distinct phases of disease progression,
namely, only local primary tumor invasion (Molife et al.,
2001), lymphogenous metastasis (Richardson et al., 1999), or
hematogenous metastasis (Scoggins et al., 2006). However,
we demonstrate that females are at a significantly lower risk
of both lymph node and distant metastases when compared
with males, even when adjusted for relevant prognostic
factors. The largest gender difference was a 450% risk
reduction of visceral (mostly liver, lung, and brain) metastases
(Table 3). This lower risk for visceral metastases explains the
largest part of the female survival advantage, as the gender
HR for melanoma-specific survival after first diagnosis (HR
0.62; Table 2) decreases considerably after the occurrence of
visceral metastasis (HR 0.88; Table 4). Even after lymph node
metastasis, females remain at a lower risk for subsequent
distant metastasis, as indicated by their persisting survival
advantage. Our results confirm the hypothesis that mela-
noma cells in females are at lower risk of disseminating,
overcoming circulation, and establishing metastases at any
site (Kemeny et al., 1998; Nieto et al., 2003; Daryanani et al.,
2005). Importantly, male gender is also associated with rapid
growth of the primary melanoma (Liu et al., 2006; Tejera-
Vaquerizo et al., 2009), although this was linked to a higher
proportion of nodular melanoma, which we did not observe
among males (Table 1).
The female survival advantage may persist even after
spread to visceral organs, as suggested by our finding of a
borderline significant effect of gender (HR 0.88, 95% CI
0.76–1.03, Table 4). Unfortunately, this analysis in stage IV
patients was limited by the small sample size and missing
information on important confounders, i.e., tumor burden
and performance score. A few studies using stage IV trial
databases were able to adjust for these confounders, but they
yielded conflicting results: one meta-analysis (n¼813) did
not reveal a significant effect of gender, but five of nine
reviewed studies reported gender as a prognostic indicator
(Unger et al., 2001). Another meta-analysis (n¼1,278)
showed a positive effect of female gender on prognosis of
patients with stage IV melanoma (HR 0.78; Po0.0001; Korn
et al., 2008). Female patients with brain metastases have also
been reported to exhibit better survival (Hofmann et al., 2007).
On the basis of both our results and the literature, we believe
that a small independent female survival advantage persists in
stage IV that is significant when a study sample is large enough.
According to our results, however, this might not be true for
survival after liver metastasis (HR 1.06; Table 4).
Table 3. Disease progression after melanoma diagnosis: multivariable disease-free survival analysis comparing
females with males1
Crude HR Adjusted HR3 Fully adjusted HR4
End point Events (%)2 HR 95% CI HR 95% CI Included confounder(s)3 HR 95% CI
Any first melanoma recurrence 2,191 (18.7) 0.66 0.61–0.72 0.69 0.63–0.75 Breslow, body site 0.68 0.62–0.75
Local recurrence 476 (4.1) 0.95 0.80–1.14 0.86 0.71–1.03 All confounders were included 0.86 0.71–1.03
In-transit/satellite metastasis 124 (1.1) 1.28 0.90–1.83 0.92 0.63–1.34 YOD, Breslow, histology, body site 0.90 0.62–1.32
Lymph node metastasis 1,321 (11.3) 0.58 0.52–0.65 0.58 0.51–0.65 Breslow, body site 0.58 0.51–0.65
Distant metastasis 1,602 (13.7) 0.61 0.55–0.67 0.64 0.57–0.71 Breslow, body site 0.64 0.58–0.71
Distant skin metastasis 321 (2.7) 0.83 0.66–1.03 0.75 0.59–0.94 Breslow, histology, body site 0.74 0.59–0.94
Distant LN metastasis 200 (1.7) 0.76 0.58–1.01 0.67 0.50–0.90 Breslow, body site 0.68 0.51–0.92
NOS 182 (1.6) 0.75 0.56–1.00 0.82 0.61–1.09 Breslow 0.85 0.63–1.16
Visceral 899 (7.7) 0.50 0.43–0.57 0.53 0.46–0.61 Breslow 0.56 0.49–0.65
Liver 220 (1.9) 0.49 0.37–0.64 0.53 0.40–0.70 Breslow 0.54 0.40–0.72
Lung 344 (2.9) 0.44 0.36–0.57 0.47 0.40–0.60 Breslow 0.50 0.40–0.64
Brain 188 (1.6) 0.49 0.36–0.66 0.53 0.39–0.71 Breslow 0.58 0.42–0.79
Other visceral 147 (1.3) 0.66 0.48–0.92 0.73 0.52–1.03 Breslow, body site 0.74 0.53–1.05
Abbreviations: CI, confidence interval; HR, hazard ratio; LN, lymph node; NOS, not otherwise specified; YOD, year of diagnosis.
1All HRs were calculated for females compared with males as reference category.
2Absolute number of events and the percentages of the total of 11,734 patients.
3The following confounders were tested: age, YOD, primary tumor Breslow thickness (in AJCC (American Joint Cancer Classification System) categories),
histology, and body site. If a confounder adjusted the male excessive risk of death byX10%, it was considered an eligible confounder and was added to the
adjusted Cox proportional hazards model.
4Adjusted for age, YOD, primary tumor Breslow thickness, histology, and body site.
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In summary, either a protective factor in females or a
melanoma-stimulating factor in males seems to be respon-
sible for an overall less aggressive course of the melanoma in
females, and, although affecting progression throughout all
melanoma stages, this gender factor seems to have the largest
effect on the risk of visceral metastases.
It is known that males, as compared with females, are less
likely to self-detect their melanomas (Liu et al., 2006), have a
lower awareness of skin cancer risk (Devos et al., 2003),
make fewer visits to health-care providers, and are less likely
to engage in preventive behaviors (Courtenay, 2000). This
results in diagnostic delays in males that probably explain
their thicker tumors, older age, and higher AJCC stage at
diagnosis, as observed in our population (Table 1) and
consistently reported throughout the literature (Lasithiotakis
et al., 2008; de Vries et al., 2008). These differences in
detection might also explain the known gender differences in
body-site distribution, i.e., more truncal melanomas in males
and limb melanomas in females (Table 1; de Vries et al.,
2008; Kemeny et al., 1998). Gender differences in survival
have long been thought to result from these differences in
detection. Our results, using the bivariate approach with the
‘‘10% rule,’’ indeed indicate that Breslow thickness and body
site considerably influenced the gender effect (Tables 2–4),
reflecting these differences in detection. However, gender
remains an independent prognostic indicator after adjustment
for these factors. Therefore, we conclude that the female
survival advantage is independent of gender differences in
detection or diagnostic delay. Another argument for this
conclusion can be found in a comparison of regions
worldwide. Although male/female incidence ratios differ
greatly across continents, the female survival advantage has
been very consistently reported in Europe (Leiter et al., 2004;
Downing et al., 2006; Lasithiotakis et al., 2008; de Vries
et al., 2008), Australia (Azzola et al., 2003), and the United
States (Kemeny et al., 1998; Balch et al., 2001b; Scoggins
et al., 2006). Therefore, incidence patterns are unlikely to
explain the female survival advantage.
Other proposed explanations for the gender difference in
melanoma survival include differences in the distribution
confounders, such as age and ulceration; influence of
estrogen in females; and the overall longevity of women.
However, all other confounders—including age and ulcera-
tion and inclusion of menopausal age groups in the subgroup
analyses—did not considerably change the gender estimates
for survival or progression and therefore do not seem to
contribute to the explanation of this phenomenon. Regarding
menopausal status, this is consistent with recent conclusions
that estrogens do not seem to affect melanoma (Gupta
and Driscoll, 2010). Finally, given that the effect of
Table 4. Survival after melanoma progression: multivariable analysis comparing females with males1
Events/no.
Crude HR Adjusted HR4 Fully adjusted HR5
Disease progression2 of patients3 (%) HR 95% CI HR 95% CI Included confounder(s)4 HR 95% CI
Any first melanoma recurrence 1,110/2,191 50.7 0.75 0.66–0.84 0.84 0.74–0.95 Body site 0.81 0.71–0.92
Local recurrence 191/476 40.1 0.69 0.52–0.92 0.73 0.54–1.00 Age, Breslow, body site 0.77 0.56–1.05
In-transit/satellite metastasis 39/121 32.2 0.54 0.29–1.02 0.39 0.16–0.95 All confounders were eligible 0.39 0.19–0.95
Lymph node metastasis 552/1,321 42.8 0.77 0.65–0.92 0.82 0.68–0.99 Breslow, body site 0.80 0.66–0.96
Distant metastasis 1,005/1,602 62.7 0.78 0.69–0.89 0.90 0.78–1.03 Body site, site of metastasis6 0.89 0.78–1.03
Distant skin metastasis 162/321 50.5 0.79 0.58–1.07 0.84 0.60–1.17 Breslow, body site 0.82 0.58–1.16
Distant LN metastasis 91/200 45.5 0.96 0.63–1.45 1.08 0.67–1.74 All confounders were eligible 1.08 0.67–1.74
NOS 128/182 70.3 0.79 0.55–1.12 0.84 0.56–1.26 YOD, Breslow, histology 0.88 0.58–1.35
Visceral7 822/899 91.4 0.84 0.73–0.97 0.87 0.74–1.01 Body site 0.88 0.76–1.03
Liver7 206/220 93.6 1.01 0.76–1.35 1.06 0.76–1.48 All confounders were eligible 1.06 0.76–1.48
Lung7 311/344 90.4 0.84 0.66–1.07 0.80 0.63–1.02 YOD, Breslow 0.84 0.65–1.09
Brain7 176/188 93.6 0.79 0.58–1.07 0.76 0.55–1.06 Age, histology, body site 0.78 0.56–1.09
Other visceral7 129/147 87.8 0.70 0.49–1.00 0.84 0.58–1.22 Age, YOD 0.85 0.58–1.25
Abbreviations: CI, confidence interval; HR, hazard ratio; NOS, not otherwise specified; YOD, year of diagnosis.
1All HRs were calculated for females compared with males as reference category.
2Follow-up starts at disease progression, and ends at lost to follow-up, malignant melanoma–specific death, or death from other causes. Hazard ratios across
gender are calculated for melanoma-specific death (= the event), except for distant visceral metastasis, where HRs for overall survival (death of all causes)
were calculated.
3No. of observed deaths/no. of patients with disease progression.
4The following confounders were tested: age as continuous variable, YOD as continuous variable, primary tumor Breslow thickness (in AJCC (American Joint
Cancer Classification System) categories), histology, and body site. For ‘‘first progression,’’ the type of progression was also tested. For ‘‘distant metastasis,’’
‘‘distant metastasis (visceral/NOS),’’ and ‘‘visceral metastasis,’’ a variable containing the subdivision of sites of these metastases was also tested. If a
confounder adjusted the male excessive risk of death by X10%, it was considered an eligible confounder.
5Adjusted for age, YOD, primary tumor Breslow thickness, histology and body site, and site of metastasis (if applicable).
6Site of distant metastasis (in categories: skin/distant lymph node/visceral/NOS).
7Survival analysis was performed for the end point overall survival instead of melanoma-specific survival.
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gender was more pronounced in melanoma-specific survival
than in overall survival, the overall superior longevity of
women is unlikely to explain their survival advantage in
melanoma.
A major strength of our study is that we used a large
population-based cancer registry that uniquely recorded
different types of disease progression during follow-up
through a meticulously refined system of follow-up. Illustrat-
ing the accuracy and validity of the MCR, the survival rates
and effect of known confounders on survival within the
registry highly resembled the results of the AJCC validation
studies (Balch et al., 2001a, 2001b).
Our study is limited by a lack of information on some
confounders, including sentinel node biopsy and, for a large
group of patients, ulceration. However, for the analyses with
the subgroup with known ulceration status, survival curves
were very similar to those in the AJCC 2001 validation study
(Balch et al., 2001b), bolstering their validity. Furthermore,
we did not have information concerning mitotic rate of the
primary, number of involved lymph nodes, and lymph node
tumor burden, which are all included in the latest AJCC
staging system (Balch et al., 2009). The 30% of all melanoma-
specific deaths without a distant metastasis registered during
follow-up suggests a 30% rate of underreporting of metas-
tasis. However, this is common in melanoma and unlikely to
be associated with gender (i.e., a nondifferential misclassifi-
cation bias).
Although the female advantage is consistently significant,
the effect on prognosis is modest. For example, the 10%
difference across gender for 10-year overall survival is small
compared with the 50% higher survival rate for thin versus
thick melanomas (o1mm and44mm; 10-year survival rates
84 vs. 34%). Illustratively, Balch et al. (2001b) ranked gender
as the sixth most important prognostic indicator. However,
the gender effect is intriguing because it is so consistent and
the cause remains unknown. To date, only one hypothesis
has been published proposing that reactive oxygen species
underlie this phenomenon (Joosse et al., 2010).
MATERIALS AND METHODS
Setting
The MCR has been registering incident cancers in Munich since
1978, gradually extending to the surrounding region of Bavaria (3.8
million inhabitants), becoming population based in 1988. Incidence
and primary tumor information (i.e., tumor–lymph node–metastasis
(TNM) stage and histological tumor characteristics) are ascertained
through pathology laboratories. Furthermore, clinicians complete
standardized forms concerning patient characteristics, tumor diag-
nosis, TNM stage, information about therapy, and follow-up. Vital
status is recorded by physicians and validated by yearly checks with
the Bavarian registry of death certificates and the municipal
registration offices.
Case ascertainment and available data
All melanomas diagnosed between 1978 and 2008 were extracted
from the MCR database (n¼ 15,859). The last complete check of
vital status was performed on 20 September 2007; hence, melanoma
cases diagnosed after 20 September 2006 were excluded so that
information on at least 1 year of follow-up would be available for all
patients. For patients with multiple melanomas, only the first
invasive melanoma was used as the starting point of follow-up.
In situ melanoma, lentigo maligna, noncutaneous melanoma,
unknown primaries, and patients without follow-up were excluded
(Table 5). For all eligible cases (n¼ 11,734), date of diagnosis,
patient characteristics, primary tumor characteristics, last known
vital status, and cause of death were available. During follow-up, the
occurrence of first progression (if any) and four distinct types of
disease progression (local recurrence, in-transit/satellite metastasis,
lymph node metastasis, and distant metastasis) were recorded
(Table 1). Distant metastasis was subcategorized into visceral (i.e.,
lung, liver, brain, and other organs), distant skin, distant lymph
nodes, and ‘‘not otherwise specified’’ metastasis. Because the
diagnosis date was available only for the first distant metastasis
diagnosed (marking progression to stage IV), subgroup analyses
using the sites of distant metastasis (e.g., liver and lung) were based
on the first distant metastasis only. Variables indicating the time from
diagnosis to progression were calculated for all types of disease
progression, and were coded ‘‘0’ if patients presented with
metastasis at the time of diagnosis. Death due to melanoma was
defined using information obtained from the death certificate or from
the clinics, or if a distant melanoma metastasis was recorded prior to
death of unknown cause.
Statistical analysis
We used w2 and Student’s t-test to compare categorical and
continuous variables, respectively. Kaplan–Meier tables were used
Table 5. Exclusion of patients with melanoma
recorded in the MCR 1978–2008
Number of melanomas %
Total melanoma patients 15,859 100
Exclusion criteria
Diagnosis after 20 September 2006 1,128 7.1
In situ melanoma1 1,969 12.4
Non-skin melanoma2 129 0.8
Unknown primary3 312 2.0
Assumed unknown primary4 154 1.0
Multiple melanomas5 432 2.7
No follow-up available 1 o0.0
Included patients 11,734 74.0
Abbreviation: MCR, Munich Cancer Registry.
1Coded as in situ in TNM stage variable or coded as ‘‘in situ melanoma,’’
‘‘lentigo maligna,’’ or ‘‘nevus’’ in the histological classification variable.
2Coded as mucosal or genital melanoma in body site classification.
3Coded ‘‘unknown primary,’’ or as a visceral primary location in the body
site classification.
4When no data were available for all of the following variables: TNM
T-stage, Breslow thickness, body site, and histological subtype, the
melanoma was excluded, and was assumed to be an unknown primary.
5The second and any subsequent primary melanomas of one patient
extracted from the registry were excluded; i.e., only the first invasive
melanoma was included.
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to calculate crude 10-year overall survival rates. Cox regression
models were used to calculate crude and adjusted HRs and 95% CIs
for females compared with males, censoring cases that were lost to
follow-up and, if applicable, cases with a non-melanoma-related
cause of death. These survival analyses were performed separately
for different phases in melanoma disease progression: (i) from
diagnosis to overall or melanoma-specific death, (ii) from diagnosis
to different end points of disease progression, and (iii) from diagnosis
of disease progression to melanoma-specific death. For survival
between visceral metastases and death, overall survival instead of
melanoma-specific death was used as an end point to increase
power, assuming that virtually all patients diagnosed with visceral
metastases ultimately die of melanoma. The proportional-hazard
assumption was checked by plotting log-minus-log plots for all
confounders in all analyses, followed, if necessary, by landmark
analysis to check the extent of nonproportionality (Harrell, 2001).
This yielded one minor violation: gender effect showed some
variation over time in log-minus-log plots, but only in the analysis
concerning overall survival. Landmark analysis revealed that the
effect of gender on overall survival was most profound in the early
years after diagnosis (HR 0.60 for 0–4 years after diagnosis) and
decreased significantly over time (HR 0.78 for 44–20 years after
diagnosis, data not shown). For all other analyses, the proportional-
hazard assumption was not violated. All statistical tests were two-
sided. P-values o0.05 were considered significant. Statistical
analysis was performed using SPSS 15.0.0 (SPSS, Chicago, IL).
Confounders
Available confounders for melanoma progression included age
(continuous variable), year of diagnosis (continuous variable),
Breslow thickness categorized according to the AJCC 2002 staging
system (Balch et al., 2001a), histological subtype, primary tumor
body site, N and M classification at the time of diagnosis, and—after
disease progression—the type of progression or site of distant
(visceral) metastasis. For categorical variables, categories are
described in Table 1. As recommended by the STROBE (Strengthen-
ing of Reporting of Observational Studies in Epidemiology) guide-
lines for reporting of epidemiological studies (Vandenbroucke et al.,
2007), and to determine which confounders influence the gender
difference, all available and appropriate confounders for each
survival analysis were first separately tested in bivariate Cox models
along with gender. If a confounder adjusted the HR of gender by
X10%, it was included in the multivariable Cox regression model. To
confirm that the nonincluded confounders indeed did not influence the
gender estimate, a second multivariable ‘‘fully adjusted’’ model was
performed, adjusting for all available confounders.
Ulceration of the primary tumor, which is an important factor in
the current AJCC staging system (Balch et al., 2001a), was excluded
from our main analyses, as it was unknown for 63% of cases,
especially in the earlier years of the study. However, subgroup
analyses using only patients with known ulceration status (n¼ 4,313)
were performed to explore the effect of this important prognostic
indicator on melanoma gender differences. Furthermore, to explore
the potential influence of menopause, subgroup analyses were
performed adjusting the gender estimate for a proxy of female
menopausal status using age at diagnosis: premenopausal was
defined asp45 years old (n¼ 3,239), menopausal as445 ando60
years old (n¼ 3,312), and postmenopausal as X60 years old
(n¼ 5,183).
To validate the MCR database and the influence on survival of
important prognostic factors included in the AJCC staging system,
survival plots of all MCR cases stratified by stage I through IV were
compared with those published by the AJCC melanoma group (Balch
et al., 2001a, b). This was repeated for survival plots stratifying for
AJCC substages according to ulceration—if available—in stages I
and II (IA–IIC) and site of metastasis in stage IV (M1–M3).
Unfortunately, stage III patients could not be substaged because of
missing information on the number of positive lymph nodes.
This cohort study is reported according to the STROBE guidelines
(Vandenbroucke et al., 2007).
CONCLUSION
In our population-based study, gender independently affected
melanoma in all progression phases, reflected mainly in a
reduced risk in females of visceral metastases (Figure 1),
resulting in a significantly higher survival rate in females as
compared with males. These results suggest a biological
difference across gender in the disease and/or in the
disease–host interaction. Research aimed at unraveling the
underlying mechanisms may be of therapeutic relevance.
Melanoma
diagnosis
HR 0.52;
95% CI (0.45–0.59)
HR 0.69;
95% CI (0.63–0.59)
HR 0.59;
95% CI (0.53–0.66)
HR 0.84;
95% CI (0.74–0.95)
First relapse
(Any disease
progression) Visceral
metastasis Death
HR 0.87;
95% CI (0.75–1.01)
Figure 1. The female advantage in survival as well as before and after first progression and visceral metastasis. Hazard ratios for females as compared
with males, presented in several time periods of melanoma progression related to diagnosis, disease recurrence, visceral metastasis, and death.
Lighter gray represents borderline significance; darker gray represents significance as compared with males. CI, confidence interval; HR, hazard ratio.
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